Diabetes

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC11206	HSD-016 Featured	HSD-016 (HSD016) is a potent, selective, and efficacious 11β-HSD1 inhibitor with IC50 of 149 and 530 nM for mouse and human 11β-HSD1, respectively.
DC11207	INCB13739 Featured	INCB13739 (INCB-13739) is a potent, selective, oral 11βHSD1 inhibitor (IC50=1.1 nM) with high seelctivity over other dehydrogenases, glucocorticoid and mineralocorticoid receptors..
DC11522	Imarikiren hydrochloride	A highly potent, selective, orally active renin inhibitor with IC50 of 2.1 nM in hPRA assay.
DC11933	RX 871024	A imidazoline compound that stimulate insulin release by inhibition of ATP-dependent K+ channels and inducing of Ca2+ mobilization in mouse pancreatic beta-cells.
DC11536	Imigliptin dihydrochloride	A novel potent, selective, orally available DPP-4 inhibitor with IC50 of 9 nM.
DC11898	Gosogliptin	A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM.
DC11899	Gosogliptin dihydrochloride	A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM.
DC7045	A-769662 Featured	A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity.
DC9830	AM-2394 Featured	AM-2394 is a potent and selective Glucokinase agonist (GKA), which catalyzes the phosphorylation of glucose to glucose-6-phosphate.
DC11809	APX-115 Featured	APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.
DC11174	ASP7657 Featured	ASP7657 (ASP-7657) is a potent, selective, orally active prostaglandin EP4 receptor antagonist with Ki values of 6.02 nM and 2.21 nM for rat and human EP4 receptors, resepctively.
DC11032	AZD9977 Featured	AZD9977 is a first-in-class, potent, selective, mineralocorticoid receptor (MR) modulator with IC50 of 0.37. 0.08 and 0.08 uM for human, mouse and rat MR, respectively.
DC8186	Bexagliflozin3 Featured	Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.
DC8571	BGP-15 Featured	BGP-15 is a PARP inhibitor and insulin sensitizer.
DC11842	BI 135585	BI 135585 (BI-135585, BI135585) is a potent, selective, orally active 11β-HSD1 inhibitor with IC50 of 4.3 nM and 53 nM in human adipocytes and primary human adipose tissue, respectively.
DC11761	BMS-816336	A novel potent, selective, orally active human 11β-HSD1 inhibitor with IC50 of 3.0 nM.
DC8392	BQ-123 Featured	BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
DC8089	BVT 2733(BVT.2733) Featured	BVT 2733 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor,protecting osteoblasts against endogenous glucocorticoid induced dysfunction.
DC8278	BVT-14225 Featured	BVT 14225 is a new selective 11b-HSD1 inhibitor, it belongs to a class of arylsulfonamidothiazoles with in vitro and in vivo antidiabetic effects
DC3111	Canagliflozin Featured	Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively.
DC8482	CAY10415(MSDC-0160) Featured	CAY10415 is a potent, antidiabetic drug of the TZD structural class.
DC10206	CCX140	CCX140 is a potent CCR2 antagonist.
DC6904	DAPAGLIFLOZIN Featured	Dapagliflozin, also known as BMS-512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin.
DC8108	DBPR108	DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9. IC50 value: 15 Nm.
DC11233	DS-8500a	DS-8500a (DS8500a) is a novel potent, selective, orally available GPR119 agonist with EC50 of 51.5 nM in human GPR119-expressing CHO-K1 cells, displays no significant effect on 66 receptors, channels, or transporters.
DCAPI1356	Epalrestat Featured	Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
DC8182	Bempedoic Acid(ETC-1002;ESP-55016) Featured	ETC-1002(ESP-55016) is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule; activator of hepatic AMP-activated protein kinase (AMPK); also has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
DC8118	GKT137831(Setanaxib) Featured	GKT137831 is a novel and specific dual Nox1/Nox4 inhibitor with Ki of 140±40 nM and 110±30 nM; a potent inhibitor of fibrosis and hepatocyte apoptosis.
DC10003	PF-06291874（glucagon receptor antagonists-4） Featured	glucagon receptor antagonists-4 is a highly potent glucagon receptor antagonist.
DC9299	GRA Ex-25 Featured	GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk.

Diabetes

Customized Consultation X

Your information is safe with us. * Required Fields.